Company Starts US Launch of Therapeutics

Company Starts US Launch of Therapeutics

By: Dylan Sikes – AllPennyStocks.com News

Thursday, September 8, 2022

Treatments for neurological conditions and mental disorders are limited and not always effective. This company is launching its new product, which  was developed to target the central nervous system to help with various afflictions.

Clinical life sciences company CanaQuest Medical Corp (OTC PINK:CANQF) announced the US launch of all-natural Mentanine® (cannabidiol "CBD" + IP, Omega-3s, DHA, EPA formula) in California for distribution across the United States and international export per the company’s press release. Canaquest is focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors.

The product hopes to treat neurological conditions including epilepsy, anxiety, depression and PTSD.

Shares of CanaQuest last traded at $0.15


Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Dually-Listed Junior Miner Finds Mid-Week Success
Biotech Soars on Research Collaboration And License Agreement Release
Cannabis Stocks On The Move Amid DEA Reclassification Indication
Most Popular
FREE Newsletter


Back to Top